Information Provided By: 
Fly News Breaks for December 3, 2019
EW
Dec 3, 2019 | 07:34 EDT
Morgan Stanley analyst David Lewis said he believes consensus estimates for Edwards Lifesciences "look achievable" and he sees a favorable risk/reward balance for the shares into the company's investor day meeting on December 5. The company changed its guidance philosophy this year, according to Lewis, who said he doesn't expect management to guide aggressively. For 2020, he expects revenue guidance of 10%-12% constant currency growth, versus his estimate of 11% growth. Lewis keeps an Overweight rating and $248 price target on Edwards shares.
News For EW From the Last 2 Days
There are no results for your query EW
